Boston Scientific Corporation
BSX Healthcare Medical Devices
Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024. In the quarter to June 2026, revenue grew 7.53%, EPS grew 14.8%, free cash flow grew 13.3% and total debt rose 8.95%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow BSX
Boston Scientific Corporation (BSX) Net income
Boston Scientific Corporation's net income for fiscal 2025 was $2.9B, up 56.7% from $1.8B in fiscal 2024. Over the twelve months to 30 June 2026 it was $3.7B. Over the past ten years it has ranged from −$239.0M (fiscal 2015) to $4.7B (fiscal 2019); the current reading is higher than 91% of that period. Net income has risen for 3 consecutive fiscal years. Boston Scientific Corporation ranks 4th of 149 Medical Devices companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $2.9B | 56.66% |
| FY2024 | $1.8B | 15.95% |
| FY2023 | $1.6B | 128.08% |
| FY2022 | $698.0M | (32.95%) |
| FY2021 | $1.0B | — |
| FY2020 | −$82.0M | — |
| FY2019 | $4.7B | 181.27% |
| FY2018 | $1.7B | 1,506.73% |
| FY2017 | $104.0M | (70.03%) |
| FY2016 | $347.0M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $904.0M | (32.49%) |
| Mar 2026 | $1.3B | 99.85% |
| Dec 2025 | $670.0M | (11.26%) |
| Sep 2025 | $755.0M | (5.03%) |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ABT Abbott Laboratories compare | $5.4B |
| MDT Medtronic PLC compare | $5.3B |
| SYK Stryker Corporation compare | $3.7B |
| BSX Boston Scientific Corporation | $3.7B |
| GEHC GE HealthCare Technologies Inc. compare | $2.1B |
| PHG Koninklijke Philips N.V. compare | $1.3B |
| EW Edwards Lifesciences Corporation compare | $1.0B |
| DXCM DexCom, Inc. compare | $999.7M |
| STE STERIS plc compare | $808.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on BSX
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement